Stock Track | Hims & Hers Health (HIMS) Plummets 5.03% as Competition Intensifies in Weight-Loss Drug Market

Stock Track12-16

Shares of Hims & Hers Health Inc. (HIMS), a telehealth company that offers various healthcare products and services, including weight-loss drugs, plummeted by 5.03% on Monday. This significant drop in the stock price can be attributed to the increasing competition and uncertainties surrounding the weight-loss drug market.

The weight-loss drug industry has been in the spotlight recently, with companies like Eli Lilly and Novo Nordisk competing for market share with their branded medications, Zepbound and Wegovy, respectively. However, the emergence of compounding pharmacies and telehealth platforms offering cheaper copycat versions of these drugs has posed a significant challenge to the major pharmaceutical companies.

As reported by Barron's, the Food and Drug Administration (FDA) is expected to make a crucial decision on Thursday regarding whether Eli Lilly's supply of Zepbound can meet the U.S. demand. If the FDA determines that Zepbound is not in shortage, it could potentially limit the availability of cheaper compounded versions, which have been gaining popularity among consumers seeking affordable weight-loss solutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146171330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-16 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146171330","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health (HIMS) Plummets 5.03% as Competition Intensifies in Weight-Loss Drug Market","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS), a telehealth company that offers various healthcare products and services, including weight-loss drugs, plummeted by 5.03% on Monday. This significant drop in the stock price can be attributed to the increasing competition and uncertainties surrounding the weight-loss drug market.</p>\n\n<p>The weight-loss drug industry has been in the spotlight recently, with companies like Eli Lilly and Novo Nordisk competing for market share with their branded medications, Zepbound and Wegovy, respectively. However, the emergence of compounding pharmacies and telehealth platforms offering cheaper copycat versions of these drugs has posed a significant challenge to the major pharmaceutical companies.</p>\n\n<p>As reported by Barron's, the Food and Drug Administration (FDA) is expected to make a crucial decision on Thursday regarding whether Eli Lilly's supply of Zepbound can meet the U.S. demand. If the FDA determines that Zepbound is not in shortage, it could potentially limit the availability of cheaper compounded versions, which have been gaining popularity among consumers seeking affordable weight-loss solutions.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health (HIMS) Plummets 5.03% as Competition Intensifies in Weight-Loss Drug Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health (HIMS) Plummets 5.03% as Competition Intensifies in Weight-Loss Drug Market\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-16 22:34 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Hims & Hers Health Inc. (HIMS), a telehealth company that offers various healthcare products and services, including weight-loss drugs, plummeted by 5.03% on Monday. This significant drop in...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1146171330","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146171330","pubTimestamp":1734359693,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc. , a telehealth company that offers various healthcare products and services, including weight-loss drugs, plummeted by 5.03% on Monday. This significant drop in the stock price can be attributed to the increasing competition and uncertainties surrounding the weight-loss drug market.The weight-loss drug industry has been in the spotlight recently, with companies like Eli Lilly and Novo Nordisk competing for market share with their branded medications, Zepbound an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"由于减肥药市场竞争加剧，Hims&Hers Health(HIMS)暴跌5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS), a telehealth company that offers various healthcare products and services, including weight-loss drugs, plummeted by 5.03% on Monday. This significant drop in the stock price can be attributed to the increasing competition and uncertainties surrounding the weight-loss drug market.\nThe weight-loss drug industry has been in the spotlight recently, with companies like Eli Lilly and Novo Nordisk competing for market share with their branded medications, Zepbound and Wegovy, respectively. However, the emergence of compounding pharmacies and telehealth platforms offering cheaper copycat versions of these drugs has posed a significant challenge to the major pharmaceutical companies.\nAs reported by Barron's, the Food and Drug Administration (FDA) is expected to make a crucial decision on Thursday regarding whether Eli Lilly's supply of Zepbound can meet the U.S. demand. If the FDA determines that Zepbound is not in shortage, it could potentially limit the availability of cheaper compounded versions, which have been gaining popularity among consumers seeking affordable weight-loss solutions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146171330"}